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CHANGES IN FECAL LACTOFERRIN AS A PREDICTOR OF STEROID 
RESPONSIVENESS IN PEDIATRIC PATIENTS WITH ULCERATIVE COLITIS 
 
SEAN T. MURPHY 
 
ABSTRACT 
 
INTRODUCTION: The management of pediatric patients with ulcerative colitis (UC) is 
dependent upon the ability to detect meaningful changes in disease status. This is 
currently done using validated patient-reported clinical disease activity indices, including 
the Pediatric Ulcerative Colitis Activity Index (PUCAI). While useful for global 
assessments completed during ambulatory office visits, the sensitivity of this metric may 
be insufficient to reflect more subtle changes in disease activity or response to medical 
therapy in hospitalized patients. Intravenous steroids are typically employed in the 
management of patients admitted for acute exacerbations of UC symptoms. These are 
typically manifest by worsening bloody diarrhea, abdominal pain, and worsening anemia. 
There is presently no way of predicting whether a patient admitted for UC will respond to 
steroid therapy. Current paradigms dictate a five-day trial before considering a transition 
to more potent medical or definitive surgical approaches to the management of refractory 
colitis. The development of more sensitive and reliable biomarkers or disease activity 
metrics could enable clinicians to more expediently identify steroid non-responders. This 
would minimize patient morbidity, decrease risk of complication, and lower overall cost 
of care. Previous studies have demonstrated that changes in fecal lactoferrin (FLA) 
correlate with disease activity in patients with UC. 
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OBJECTIVES: To analyze the predictive value of FLA in the response to steroid 
treatment of patients admitted for management of UC. 
 
METHODS: We recruited pediatric inpatients with UC in the Division of 
Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital who were 
hospitalized for treatment of a flare of their UC symptoms. After obtaining patient 
consent, we collected a stool sample on days 1 and 3 of their hospital stay. We sent 
samples to TECHLAB® Inc. (Blacksburg, VA) to be analyzed for levels of FLA. We 
compared Day 1, Day 3 and ∆FLA (Day 1 – Day 3) in two patient groups: those that 
responded to conventional steroid therapy and those that required rescue medical or 
surgical therapy. We reported statistical significance with the Wilcoxon signed-rank test. 
 
RESULTS: Of 67 patients consented for the study, 30 provided stool samples on both 
days 1 and 3 of their inpatient hospitalization. Of the 30 patients, 63.3% responded to 
steroids while 36.7% required rescue therapy with immunomodulators. ∆FLA for 
responders, 43.6µg/mL(-239.0, 331.6) (median(interquartile range)), did not differ 
significantly from non-responders, -74.1µg/mL(-296.7, 221.7), P = 0.3. 
 
CONCLUSIONS: Our findings do not demonstrate that measurement of changes in 
quantitative FLA over three days can be used to assess acute responses to steroid therapy. 
Increasing the sample size may allow us to better delineate subtle differences between 
responders and non-responders to steroid therapy. 
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INTRODUCTION 	
Inflammatory Bowel Disease (IBD) is a well characterized yet poorly understood 
condition resulting in a chronic inflammatory process limited to the gastrointestinal (GI) 
tract. Though our understanding of the pathogenesis of this disorder is evolving, studies 
to date suggest that the disease is the result of a genetic vulnerability manifest as an 
abnormal response to non-pathogenic bacteria in the lumen of the small and large 
intestine. The first step in the characterization of IBD is the differentiation between the 
two types of this disorder: ulcerative colitis (UC) and Crohn’s disease (CD). Sir Samuel 
Wilks was the first physician to use the term “ulcerative colitis” in a case report written in 
1859. Burrill B. Crohn later published his seminal manuscript in 1932, describing the 
presentation of "regional enteritis," though the eponym was credited to him shortly 
thereafter (Mulder et al., 2014). 
 IBD affects people of all ages but is most commonly diagnosed between the ages 
of 15 and 30 (“Crohn's & Colitis Foundation of America (CCFA),” n.d.). Affected 
patients typically present with characteristic signs and symptoms including: diarrhea, 
abdominal pain, bloody stools, stool urgency, fatigue, fever, nausea, weight loss and 
anemia (“National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),” 
n.d.). The precise pathophysiology of IBD remains unknown, and current efforts are 
directed at discerning the genetic and environmental factors that are precipitating and 
maintaining the apparent overactivity of the immune cells operant within the lining of the 
gastrointestinal tract in these patients (“Diseases & Conditions - Medscape Reference,” 
n.d.). 
	 2 
Crohn’s Disease 
 Crohn’s disease is a form of IBD that can present with inflammation affecting any 
region of the GI tract. However, the majority of patients will present with disease 
involving the terminal ileum, cecum, and ascending colon. The inflammation observed in 
patients with Crohn's disease can be noncontiguous, and as such appear in a patchy 
distribution along the length of the stomach and small/large intestine with diseased areas 
separated by grossly and histologically normal appearing intervening mucosa. The 
disease can involve all layers of the GI wall including the mucosa, submucosa, 
muscularis externa, and serosa. Non-necrotizing granulomas can be identified 
histologically in approximately 20% of patients with Crohn's disease, and this finding is 
almost pathognomonic of the disease. Endoscopically, CD manifests with gross linear or 
serpiginous ulcers, which give the mucosa what is described as a “cobblestoned” 
appearance (“Diseases & Conditions - Medscape Reference,” n.d.). 
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 Table 1. Distinguishing Ulcerative Colitis from Crohn's Disease 
(Table adapted from emedicine.medscape.com) 
 Ulcerative Colitis Crohn's Disease 
Geography of Disease Disease limited to the 
colon  
Disease involving any 
portion of the GI tract 
Distribution of 
Inflammation 
Inflammation that extends 
in a continuous fashion, 
beginning in the rectum 
and extending proximally  
Inflammation is 
discontinuous with skip-
lesions of normal 
intervening mucosa 
Depth of Inflammation Inflammation limited to the 
mucosa and submucosa  
Inflammation is transmural  
Characteristic Histology Crypt Abscesses Noncaseating granulomas 
Diagnostic Serology Perinuclear ANCA 
(pANCA) positive staining 
Antibodies to S. cerevisiae 
(ASCA) 
Clinical Presentation Bleeding (common) Bleeding (uncommon) 
Penetrating Disease Fistulae (rare) Fistulae (common) 
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Ulcerative Colitis 
 Ulcerative colitis, the second subset of IBD, affects only the mucosa lining the 
colon. This inflammation is contiguous, typically beginning in the rectum and 
terminating at any point up to the level of the ileocecal valve. The type of UC is 
characterized based on the extent of colonic involvement, and disease extending proximal 
to the splenic flexure is considered pancolitis. UC with inflammation that spares the 
splenic flexure is termed "left-sided." Unlike CD, the inflammation in patients with UC 
only affects the mucosa and submucosa of the large intestine. Endoscopically, UC 
appears as hyperemic mucosa with superficial erosions. Blood, pus, or mucus can cover 
the mucosa signifying worsening disease activity (“Diseases & Conditions - Medscape 
Reference,” n.d.). Differentiating between the two types of IBD (Crohn's vs. UC) is 
necessary to both implement the most appropriate therapeutic regimen and to provide the 
most expedient anticipatory health guidance to the patient and referring primary care 
provider. 
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A. B. 
  
C. D. 
Figure 1. Colon Gross Images and Histology. (A.) Normal appearing colon. (C.) Colon 
affected by UC, showing bowel-wall thickening and foreshortening as well as hyperemic 
mucosa. (D.) Terminal Ileum segment affected by CD, showing “cobblestone” change of 
the mucosa, containing fissures and crevices. (B.) Histological section of colon with 
labeled overlay, showing the unique layers of the intestinal wall. (Figure and caption 
compiled from diomedia.com, emedicine.medscape.com, and bu.edu/histology.) 
 
 
 
 
 
 
 
 
 
 
	 6 
Following patients with UC 
 The first step in treating patients with UC is ensuring a proper clinical diagnosis. 
Currently, IBD diagnosis relies on a combination of a detailed analysis of a patient’s 
family and medical history, physical exam, lab tests, and colonoscopy results. Current 
treatment of UC occurs in two phases: induction and maintenance, and both are directed 
at controlling disease activity, alleviating symptoms, and preventing long-term 
complications. More potent agents, such as corticosteroids, are used during the induction 
phase in an effort to get disease symptoms under control as quickly as possible. Other 
induction agents fall under the categories of aminosalicylates, immunosuppressives, and 
biologics. Once UC symptoms are under control, patients are transitioned to less 
aggressive (and less toxic) maintenance medications to keep their disease in check. 
Maintenance agents may also include aminosalicylates, immunomodulators, and biologic 
agents. Some induction agents are also useful in maintaining disease in remission. When 
used for this indication, these agents are typically administered less frequently or at lower 
doses to achieve adequate disease control without incurring the risk of adverse effects 
associated with higher doses (Rufo et al., 2012). When symptoms of colitis can no longer 
be managed medically, and some patients have inflammation that proves refractory to 
steroid or other "rescue" medical therapies, surgical removal of the colon, or colectomy, 
is recommended (Dayan et al., 2012). The percentage of patients eventually receiving a 
colectomy for final treatment of UC is dependent upon the extent of the disease’s location 
and severity at diagnosis (Aloi et al., 2013). Colectomy has the added advantage of most 
definitely addressing the increased risk of colorectal cancer associated with UC. 
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 Clinicians rely on a combination of endoscopic studies, serologic and fecal 
biomarkers, as well as patient-reported metrics to monitor a patient’s disease activity and 
prognosis. Colonoscopy and biomarkers provide objective measures of a patient’s disease 
while a patient-reported score, such as the Pediatric Ulcerative Colitis Activity Index 
(PUCAI), provides doctors with a more subjective measure of ongoing response to 
therapy (Turner et al., 2007). Colonoscopy includes both gross and histological 
observation of a patient’s colon. Serum and fecal biomarkers are proteins that reflect the 
degree of inflammation in the colon without relying on more invasive, morbid, and 
expensive endoscopic studies. In the serum, both the erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP), as well as albumin are useful markers of 
inflammation in the body. Fecal lactoferrin (FLA) and calprotectin have emerged in 
recent years as the most promising objective measures of the inflammatory status of the 
intestine. In contrast, PUCAI scores are a validated subjective measure of a patient’s 
current disease status. PUCAI is based on a composite score inclusive of a patient’s 
report of abdominal pain, rectal bleeding, stool consistency, number of stools per day, 
nocturnal stools, and activity level (Turner et al., 2009). Since its development, PUCAI 
has been very useful in making clinical decisions regarding a patient’s UC disease status. 
However, due to the subjective nature of the index, the scores may not always accurately 
reflect a patient’s disease activity level. The subjective nature of the PUCAI has driven 
research studies to define alternate or complementary fecal and serologic biomarkers to 
more objectively report on a patient’s disease status and response to therapy. 
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Non-invasive markers 
 Serum markers have been the standard for assessing disease status without relying 
on invasive or time-consuming procedures. Markers like ESR and CRP give doctors 
information about the presence or absence of inflammation in the body. However, 
because serum markers are reflective of disease occurring anywhere in the body, they 
lack the specificity requisite to reliably assess changes in GI disease activity. Recent 
studies have identified a number of fecal biomarkers as sensitive and likely more specific, 
metrics of disease activity in the gastrointestinal tract, due to their derivation as direct 
products of the intestinal inflammatory response. FLA and calprotectin are the most 
commonly used fecal biomarkers used to diagnose and monitor patients with known or 
suspected IBD. 
Fecal Lactoferrin 
 FLA is a transferrin found in human breast milk and made by human mammary 
gland cells. Neutrophils and unique epithelial cells also excrete it. Sudo et. al first 
described FLA in patients with IBD in a 1993 study that looked at levels in UC patients. 
Since then, research has sought to demonstrate the sensitivity and specificity of FLA as a 
marker for GI disease activity. FLA is found in the stool, in patients with UC, due to the 
increased permeability of the GI tract that occurs as a result of inflammation. The 
presence of neutrophils at the site of acute inflammation makes FLA a valuable 
biomarker in determining inflammatory activity in a diseased colon. It is found in the 
stool in an unchanged form due to its resistance to certain proteases (Iyer et al., 1993). A 
study by Borkowska et. al (2015) compared FLA levels in patients with moderate IBD to 
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those with mild or inactive disease. They showed significantly higher levels of FLA in 
those patients with moderately active disease. FLA levels were also significantly higher 
in patients who tested positive for fecal occult blood, than in patients who tested negative 
for GI tract bleeding. A study by Buderus et. al (2015) compared FLA levels with 
endoscopic severity scores in patients with CD. Similarly, Mankowska-Wierzbicka et. al 
(2015) compared FLA levels with the Mayo endoscopic index in patients with UC. Both 
studies found an overall positive correlation between FLA levels and disease activity in 
patients with IBD. Wang et. al (2015) performed a meta-analysis to measure the 
specificity and sensitivity of FLA as a marker for identifying patients with IBD. Their 
research showed FLA specificity as 100% for the diagnosis of IBD and 75% and 82% for 
the diagnosis of CD and UC, respectively. Stragier and Van Assche (2013) discussed the 
role of FLA in predicting clinical relapse in a patient with IBD. In their review, they 
show a significant relationship between heightened FLA levels and endoscopic disease 
activity. 
Calprotectin 
 Røseth et. al first described calprotectin and the method of its extraction and 
quantification from stool in 1992. Like FLA, calprotectin is a neutrophil-derived protein 
that is released into the stool in response to inflammation (Saha et al., 2016). Due to its 
large concentration in the neutrophil cytosol, its level in the stool is directly proportional 
to the influx of neutrophils to a site of inflammation, thus enabling an estimation of the 
amount of inflammation present in the colon. Wright et. al (2016) compared the accuracy 
of FLA and calprotectin as biomarkers in patients with CD. Their results concluded that 
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calprotectin was the optimal biomarker for monitoring disease activity in postoperative 
CD. Stragier and Van Assche’s (2013) also comment on the utility of measuring fecal 
calprotectin levels to differentiate patients with active and inactive gastrointestinal 
inflammation (including infection), IBD, and irritable bowel syndrome (IBS). Research 
completed by Yamamoto and colleagues (2014) suggested that calprotectin may have a 
higher sensitivity and specificity than that of FLA for prediction of UC relapse. 
Pediatric Ulcerative Colitis Activity Index (PUCAI) 
 PUCAI is a non-invasive patient-reported measure of UC disease activity. Turner 
et. al developed the index in 2007 in an effort to provide clinicians with a standardized 
metric for assessing disease activity in pediatric patients with UC. The PUCAI is a 
composite score derived from patient report along six dimensions (abdominal pain, rectal 
bleeding, stool consistency, number of stools per 24 hours, presence or absence of 
nocturnal stools, and activity level) over the previous 24-hour period. PUCAI scores 
categorize disease activity on a spectrum that includes severe, moderate, mild, or clinical 
remission (Turner et al., 2009). PUCAI’s feasibility, validity, and responsiveness were 
confirmed in a population of 2503 patients in a 2015 study by Dotson et. al. 
Patients with UC are tracked using a combination of serologic and fecal 
biomarkers, as well as PUCAI scoring, to determine UC disease activity and response to 
therapy. 
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Hospitalized patients refractory to steroids 
 Steroids are used in the treatment of “flares” or exacerbations of clinical 
symptoms in patients with UC. Steroids are intended to manage acute symptoms, and 
serve as a pharmacologic bridge to permit the selection and implementation of other 
agents that are more appropriate for the maintenance of disease remission. However, 
treatment with steroids is not effective for every patient. Approximately 40% of patients 
treated with steroids prove refractory and require “rescue” with a different, typically 
more potent, medical therapy. Rescue therapies include immunosuppressive agents 
including the calcineurin inhibitors cyclosporine and tacrolimus, as well as the biologic 
anti-TNF agents infliximab, adalimumab, and golimumab (Protic et al., 2014). Currently, 
there is no established way to readily predict whether a patient will respond to steroid 
therapy. Instead, the current standard of practice is to monitor changes in clinical 
symptoms for days to weeks after beginning steroid therapy.  
The aim of this study is to determine if a patient’s response to steroid induction 
therapy (as assessed by FLA levels measured on days 1-3 of hospitalization), provide 
physicians with new information that can be used to expedite clinical care and/or the need 
for surgical rescue (colectomy). 
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Future monitoring of UC 
 Current UC disease monitoring relies heavily upon patient report to make an 
assessment of a patient’s disease activity. Blood tests and endoscopic studies are valuable 
objective tests for use in assessing changes in disease activity and response to medical 
therapy. However, the use of PUCAI introduces an element of subjectivity to IBD disease 
monitoring. Patients may incorrectly report their symptoms, resulting in an inaccurate 
PUCAI score. The subjectivity of using PUCAI scores in a clinical setting has the 
potential to introduce misinformation into the clinical decision algorithm, thereby leading 
to mismanagement of UC. The goal of physicians and clinical researchers is to reduce 
subjectivity involved in clinical measures of UC. Fecal biomarkers are an attractive 
method of assessing disease status as they objectively assess disease activity in patients 
with UC. This study seeks to further understand the potential of FLA as a useful 
biomarker in objectively monitoring changes in disease activity in patients with IBD. 
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OBJECTIVES 
 
Fecal biomarkers have been established as valid metrics for assessing IBD disease 
activity. However, the information provided by fecal biomarkers has only recently been 
included in clinical care. As such, clinicians are only now working to include FLA and 
fecal calprotectin measurements in clinical algorithms. Current methods of evaluating UC 
disease activity rely on using PUCAI, a patient-reported metric. With the potential for 
subjectivity to cloud the validity of PUCAI, there is a need to develop and standardize 
complementary, and perhaps more effective, indicators of disease activity in this patient 
population. 
This study will assess the use of FLA in monitoring disease activity in patients 
hospitalized for treatment with parenteral steroid therapy for a flare of their UC. We 
hypothesize that not absolute values, but changes in FLA levels over time, can predict 
whether or not a patient is responding to steroid therapy. In this study, we compared the 
differences between FLA levels on Day 1 and Day 3 of hospitalization in two inpatient 
populations: those that responded to conventional steroid therapy and those that required 
rescue medical or surgical therapy. This should enable clinicians to know by Day 3 of 
hospitalization whether or not their patient is likely to be a responder or a non-responder 
to steroids. If patients are identified early as being refractory to steroids, they can be more 
expediently transitioned to alternative/more intensive rescue therapy. As such, this 
approach can help minimize patient morbidity, decrease risk of complication, shorten 
inpatient stays, and lower overall cost of care. 
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Overall, studies of this type, aimed at decreasing subjectivity in IBD medical 
treatment, will help to improve quality of care and decrease the amount of time needed to 
determine the efficacy of steroid therapy per patient. We aim to demonstrate FLA as an 
objective measure of a patient’s UC disease activity status as it relates to response to 
steroid therapy. 
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METHODS 	
Study Population 
Pediatric patients (≤21 years of age) with a known or suspected diagnosis of UC 
were recruited from the Gastroenterology inpatient service at Boston Children’s Hospital. 
The definition of UC, including disease subtypes (ulcerative proctitis, distal UC, or 
pancolitis) was assessed using standard clinical, endoscopic, histological, and 
radiological standards. Patients with CD, undetermined intestinal malignancies, or a 
medical history of total colectomy were excluded from study participation. Additionally, 
patients who were diagnosed with HIV and/or Hepatitis B or C were deemed ineligible. 
 
Recruitment Methods 
Patient eligibility was determined using Boston Children’s Hospital’s electronic 
medical record database, PowerChart (by Cerner®), in conjunction with clinical 
interactions among GI inpatient service physicians and nurses. We approached eligible 
patients on the GI inpatient floor. Patients <18 years of age required parental consent in 
addition to their own assent while patients ≥18 years of age did not require parent 
consent. We met with patients and parents (when applicable) in the patient’s room to 
discuss study requirements, procedures, and goals. Study candidates and their parents 
were given ample time to read through the consent form and ask questions. Enrolled 
subjects were assigned a unique study designation number to maintain anonymity. 
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Sample Collection and Processing 
After obtaining patient consent, we provided nurses with specimen cups to collect 
a stool sample from the patient each day they remained in the hospital. Each sample was 
stored at 4° Celsius. Collected samples were divided into three 2-mL aliquots, labeled 
with the date the sample was obtained, and stored at -80° Celsius. Samples remained in 
this freezer until they were ready for batch shipment to our testing facility, TECHLAB® 
Inc. (Blacksburg, Virginia). We shipped only one 2-mL aliquot per sample, leaving two 
in the freezer, in the event that samples were lost or required retesting at a later time 
point. 
 
Sample Testing 
Batched stool samples were shipped to TECHLAB® Inc., who provided material 
and laboratory support for the conduct of this study. TECHLAB® Inc. personnel were 
blinded to disease activity in the samples provided. Two FLA tests developed by 
TECHLAB® Inc., IBD-SCAN™ (quantitative) and IBD-CHEK™ (qualitative), were 
performed on the fecal specimens following a 1:20 dilution. IBD-SCAN™ quantifies 
FLA in micrograms/milliliter (µg/mL). A reading of ≥7.25 µg/mL was defined as an 
elevated FLA level, while values <7.25 µg/mL were considered baseline (normal). IBD-
CHEK™ confirms the presence of FLA in terms of optical density (OD) at 
450nm/620nm on a dual wavelength spectrophotometer. A reading of greater than or 
equal to 1:160 was defined as a positive result for stool samples (TECHLAB®, 2015). 
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Case Report Forms 
A Case Report Form (CRF) was used to record a patient’s data, which was 
subsequently entered into the Research Electronic Data Capture (REDCap) web 
application for Boston Children’s Hospital. The CRF (Figures 2-6) was designed to 
expedite the systematic collection of relevant patient information from the electronic 
medical record and to facilitate data entry and analysis. CRFs were completed for patients 
enrolled in the study who provided at least one stool sample. 
The study CRF included nine sections. The first four sections: general 
information, demographic information, disease information and admission information 
were completed once per patient, while the last five sections: activity index scores, fecal 
lab levels, blood work, anthropometric information and medications were completed for 
each day during a patient’s hospitalization. 
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Figure 2. Demographic Information – CRF. CRF showing demographic information 
collected for the study. 
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Figure 3. Disease and Admission Information – CRF. CRF showing information 
collected prior to patient’s participation in the study. 
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Figure 4. PUCAI, FLA and blood work – CRF. CRF showing data collected for one 
day of hospitalization. 
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Figure 5. Anthropometric Information and Medications – CRF. CRF showing 
anthropometric information and medication information collected for one day of 
hospitalization. 
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Figure 6. Conclusion and Outcome Information – CRF. CRF showing information 
entered following the conclusion of participation by patients in the study. 
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Statistical Analysis 
Patient outcome was dichotomized into two populations: those that responded to 
conventional steroid therapy and those that required rescue medical or surgical therapy. 
These two populations were compared with respect to FLA levels (IBD-SCAN™). For 
both of the populations, the mean, standard deviation, median, and interquartile ranges 
were calculated. Due to the skew in our data, non-parametric (Wilcoxon signed-rank test) 
statistical testing was used to determine the statistical significance of the differences in 
FLA levels measured in stool samples collected on Day 1 and Day 3 (∆FLA) of 
hospitalization. 
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RESULTS 	
Patient Population 
 A total of 56 patients (19 male/37 female) diagnosed with UC and hospitalized at 
Boston Children’s Hospital provided informed consent for participation in the study. Of 
these 56 patients, 50 provided a stool sample on Day 1 of their hospitalization, 32 
provided a stool sample on Day 3, and 31 provided a stool sample on both Day 1 and Day 
3. Our analysis focused on the 31 patients with samples on Day 1 and Day 3 of which 
61.3% responded to conventional steroid therapy and 38.7% did not respond and required 
rescue therapy (immunomodulator or biologic). Stool samples were quantified via the 
IBD-SCAN™ assay from TECHLAB® Inc. and analyzed for statistical significance. 
 
 
Table 2. Demographic information of the study group 
n 57 
M/F 19/38 
	 	
UC Phenotype 	
Ulcerative Proctitis 2 
Distal UC 7 
Pancolitis 47 
(control) 1 
	 	
Day 1 stool sample 50 
Day 3 stool sample 32 
Day 1 & Day 3 stool samples 31 
Steroid Responders 19 
Steroid Non-responders 12 
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Fecal Lactoferrin (IBD-SCAN™) and Discharge Outcome 
 Day 1 (Figure 7) and Day 3 (Figure 8) FLA levels (IBD-SCAN™) were collected 
and plotted for comparison. We ran descriptive statistics, which showed a Day 1 mean of 
395.60, standard deviation of 397.26, and median of 267.45 (indicated by red dot on 
Figure 7 graph) for 50 study participants. 
 
 
 
Figure 7. Day 1 FLA sample data. Descriptive statistics table and sample data graph 
from 50 patients who provided a Day 1 stool sample. The red dot on the graph represents 
a median Day 1 FLA level of 267.45. Each Y-axis unit is a different patient. X-axis units: 
µg/mL. (Figure extracted and modified from the REDCap web application at Boston 
Children’s Hospital.) 
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We showed a Day 3 mean of 413.79, a standard deviation of 378.13, and a 
median of 368.95 (indicated by red dot on Figure 8 graph) for 32 study participants. 
 
 
 
Figure 8. Day 3 FLA sample data. Descriptive statistics table and sample data graph 
from 32 patients who provided a Day 3 stool sample. The red dot on the graph represents 
a median Day 3 FLA level of 368.95. Each Y-axis unit is a different patient. X-axis units: 
µg/mL. (Figure extracted and modified from the REDCap web application at Boston 
Children’s Hospital.) 
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 Table 3 shows the median and interquartile range of FLA values for stool samples 
collected on Day 1 and Day 3 obtained using the Wilcoxon signed-rank test. On Day 1, 
for responders, we found a median of 329.4 and an interquartile range of 136.9 to 655.2. 
For non-responders, we found a median of 257.5 and an interquartile range of 99.0 to 
353.7 (P = 0.31). On Day 3, for responders, we found a median of 437.4 and an 
interquartile range of 269.6 to 525.3. For non-responders, we found a median of 215.3 
and an interquartile range of 83.4 to 415.8 (P = 0.15). 
 
Table 3. FLA levels for Responders and Non-responders on Day 1 and Day 3. 
Median (interquartile range), with P values, of IBD-SCAN™ (µg/mL) of two 
patient populations. 
 
Day 1 Day 3 
Responders (n = 19) 329.4 (136.9, 655.2) 437.4 (269.6, 525.3) 
Non-responders (n = 12) 257.5 (99.9, 353.7) 215.3 (83.4, 415.8) 
P value 0.31 0.15 
 
 ∆FLA (Day 1 – Day 3) is shown graphically for each patient in Figure 9. The 
graph connects each patient’s Day 1 and Day 3 FLA level, showing the movement of 
FLA across Day 1 and Day 3 of patients’ hospitalizations. 
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Figure 9. ∆FLA for Responders and Non-Responders. Graphical representation of 
∆FLA of 31 patients for which Day 1 and Day 3 stool samples were collected. Each line, 
connected between Day 1 and Day 3 samples, corresponds to one patient. Responders are 
denoted with circles for each sample point and yellow lines connecting each sample. 
Non-Responders are denoted with triangles for each sample point and red lines 
connecting each sample. (Figure created and edited using Microsoft Excel.) 
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 Table 4 presents the statistical analysis of ∆FLA between responders and non-
responders. Median and interquartile range are presented along with an associated P 
value comparing the two patient groups. With the Wilcoxon signed-rank test (because of 
the data skew) we found, for responders, a ∆FLA median of 43.6 and an interquartile 
range of -239.0 to 331.6 and for non-responders, a median of -74.1 and an interquartile 
range of -296.7 to 221.7 (P = 0.3). 
 
Table 4. ∆FLA levels for Responders and Non-responders. Median 
(interquartile range), with P values, of IBD-SCAN™ (µg/mL) Day 1 - 
Day 3 of two patient populations. 
 
∆FLA 
Responders (n = 19) 43.6 (-239.0, 331.6) 
Non-responders (n = 12) -74.1 (-296.7, 221.7) 
P value 0.3 			
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DISCUSSION 
 
 Inflammatory Bowel Disease (IBD) has only recently been more fully 
characterized with respect to its prevalence (about 1.7 million Americans) and 
widespread morbidity (Molodecky et al., 2012). Its pathogenesis has not been fully 
elucidated. However an interplay of environmental and genetic factors have been 
implicated (“National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK),” n.d.). IBD treatment has also undergone significant progress over the past 
several decades. Treatments have become more mechanistic and target specific pathways 
that mediate disease manifestations. The ability of a health care provider to implement 
specific treatment decisions relies heavily upon his ability to understand what stage the 
disease is in and to reliably assess disease activity. Current work-up for the diagnosis and 
identification of IBD and its subtypes involves the use of serum, fecal, and endoscopic 
studies (Rufo et al., 2012). These studies seek to confirm IBD symptomology as well as 
rule out infectious causes. Once the diagnosis of IBD is confirmed, patient-reported 
activity indices are used to monitor interval progression in response to ongoing medical 
treatment. The Pediatric Ulcerative Colitis Activity Index (PUCAI) is used to monitor 
patients with ulcerative colitis (UC) and includes patient-reported metrics such as 
abdominal pain, nocturnal symptoms and level of activity limitation associated with 
symptoms (Turner et al., 2007). During a hospitalization for acute symptoms associated 
with a flare of UC, corticosteroids are used during the induction phase of treatment, to get 
symptoms under control and allow for the institution of more appropriate long-term 
maintenance therapy (Rufo et al., 2012). However, 40% of patients are refractory to 
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steroid treatment and require rescue with a differently acting medical therapy (Protic et 
al., 2014). Currently, the determination that a patient is refractory to steroids requires 
several days of observation and analysis of a patient’s PUCAI score and serum markers. 
If PUCAI scores and inflammatory markers remain high, the patient is transitioned to a 
different induction therapy in the hopes to calm symptoms with a different medication. 
Thus, with uncertainty of a patient’s response to steroids, there is a need to develop a 
method of monitoring disease activity that is not confounded by patient-reported error. 
 Fecal biomarkers, such as fecal lactoferrin (FLA), have been demonstrated in 
several previous studies to be a direct metric for IBD disease activity (Borkowska et al., 
2015; Buderus et al., 2015; Mańkowska-Wierzbicka et al., 2015; Wang et al., 2015). FLA 
is becoming increasingly common for use in clinical practice. However, little data is 
available to discuss the use of this metric in the measurement of acute response to 
pharmacologic interventions. The goal of this study is to determine if FLA can be used as 
a predictor of response to steroids in pediatric patients with a UC flare. 
 This study was designed to assess if trends are present in FLA levels that relate to 
a response to steroid therapy. We chose Day 1 to Day 3 (∆FLA) as a critical time period 
to assess a patient’s response to steroids. If health care providers could determine if a 
patient is responding to steroid therapy by Day 3, they could save non-responding 
patients from days of continued futile medical care. Also, the resulting standard of care 
should lead to shorter hospitalizations and cost savings. The hope for this study was to 
provide health care providers with information that would enable them to make informed 
and confident decisions about whether to keep their patients on steroid therapy or escalate 
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to a more potent medical or surgical therapy based on FLA level trends from Day 1 to 
Day 3 of an inpatient hospitalization. 
 The number of stool samples acquired per patient depended on how quickly they 
recovered from the flare as well as the clinical treatment and procedure plan. For this 
reason, only 31 patients out of 57 were able to provide us with both a Day 1 and Day 3 
stool samples for analysis. For this study, we analyzed 19 responders and 12 non-
responders to steroid therapy. 
 Day 1 and Day 3 stool samples for each patient population were determined not to 
be statistically significant (P = 0.31 and P = 0.15 respectively). We then analyzed ∆FLA 
(Day 1 – Day 3) between the two patient groups. ∆FLA, we hypothesized, could be a 
more sensitive metric for use by health care providers to determine steroid responsiveness 
in patients with UC. However, we did not find a statistical significance to differentiate 
responders from non-responders (P = 0.3). 
 Figure 9 shows an overview of each paired stool sample collected in the study, 
linked by a line. We initially hypothesized that FLA levels measured in steroid 
responders (yellow) would be more likely to display a negative slope between hospital 
days 1 and 3. As such, this negative slope would correspond to a decline in UC 
symptoms. In this circumstance, there would be no need for providers to escalate to 
rescue therapy. In contrast, a flat or positive slope in FLA levels between days 1 and 3 of 
hospitalization would be more likely to occur in steroid non-responders (red lines). This 
flat or increase in the slope of the ∆FLA between Day 1 to Day 3 would thus suggest that 
a transition to rescue therapy is more warranted. However, Figure 9 shows that our 
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hypothesis does not hold and that there is not statistical significance in ∆FLA between 
responders and non-responders. 
 Despite a lack of statistical significance in ∆FLA between responders and non-
responders, the data illustrated in Figure 9 can serve as a starting point for additional 
study. The figure shows that, around a critical FLA level of 500µg/mL, the slopes of 
patients who responded to steroid therapy transition from a series of negative slopes 
above and a series of positive slopes below. The opposite is true for non-responders - 
numerous slopes have a positive slope below 500µg/mL whereas every slope beginning 
above 500µg/mL has a negative slope. This may be suggestive of a trend in the data that 
is specific to the level of FLA on Day 1 and not the trend of FLA from Day 1 to Day 3 
alone. If so, the data would suggest that measurement of FLA may be especially useful in 
certain clinical subsets. This possibility is the subject of future analysis in a branch of this 
study. 
 This study’s analysis was limited by its sample size. Lack of sufficient samples 
may be confounding our study results. With increased number of samples, we may be 
able to determine with greater certainty the correlation between changes in FLA levels 
and the clinical response to steroids during a UC flare. 
 
  
	 34 
CONCLUSION 	
 We hypothesize that the study was not able to fully demonstrate the relationship 
between ∆FLA and clinical response in patients with UC due to a suboptimal sample 
size. The Center for Inflammatory Bowel Disease at Boston Children’s Hospital will 
continue to enroll patients in the study in order to expand the sample size. With an 
adequate sample size, we may be able to determine a more accurate statistical 
significance for the difference in ∆FLA between responders and non-responders to 
steroids. 
 Along with FLA, numerous serum markers such as erythrocyte sedimentation 
rate, C-reactive protein, and albumin were collected in parallel with each stool sample. 
This blood work data can be used in conjunction with FLA to yield novel conclusions 
regarding how patients with UC, and IBD in general, can be followed. It may be possible 
to combine FLA and serum markers into one, composite metric, which could be used in 
conjunction with PUCAI to monitor day-to-day changes in disease activity. In future 
studies, we will compare trends in serum markers to those observed in FLA levels 
according to each day of hospitalization. 
 However, we also recognize that the lack of statistical significance in this study is 
indicative of FLA not being an effective marker for predicting steroid response in 
patients with UC. Our results also indicate that Day 3 may not be an appropriate time 
point to analyze FLA’s predictability. It may require 5, 7 or more days to determine 
statistical significance for FLA as a predictive measure of steroid response. Lastly, our 
results indicate that steroids may not be the adequate treatment for UC and thus, the 
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utility of FLA as a biomarker is not reflective of disease activity, as steroids do not fully 
treat UC. Improvement of symptoms in patients who respond to steroid treatment may 
not be due to an improvement in their UC, but instead an improvement in their overall 
immune system health and function. 
 FLA and related fecal biomarkers continue to be studied in an effort to better 
understand their utility and efficacy in the monitoring of IBD. Current projects focus on 
both further elucidating the relationship between FLA and IBD disease activity, while 
others seek to ascertain the predictive value of FLA for use in the prospective 
management of patients with IBD. We plan to continue our studies to better demonstrate 
the predictive value for FLA in an effort to improve the standard of care for hospitalized 
patients with IBD. We are seeking to replace existing metrics that rely heavily on patient 
subjectivity and self-report to those relying on more objective parameters including fecal 
and/or serum markers. Improved disease metrics should facilitate the development of 
increasingly cost-effective and clinically rationale approaches to patient care. 
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